New HF drug

Discussion in 'Novartis' started by Anonymous, Nov 27, 2014 at 9:18 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Predictions, fast or slow out of the gate. Will the cost of the drug prevent uptake vs ACEI.

    Will doctors believe the data, or will they feel that the data is rigged like Tekturna and Diovan.

    Should be interesting.
     

  2. Anonymous

    Anonymous Guest

    Will it be another nightmare like valturna?
     
  3. Anonymous

    Anonymous Guest

    Let's continue to find as many combinations with diovan an as we can. Going up against all generic options won't be easy.
     
  4. Anonymous

    Anonymous Guest

    I hear it will sell itself.
     
  5. Anonymous

    Anonymous Guest

    nothing sells itself......adah!!!
     
  6. Anonymous

    Anonymous Guest

    Can you say another dog.....maybe the marketing will have those stupid lanes for us on where to use it like they had with the past CV MEDS
     
  7. Anonymous

    Anonymous Guest

    Prediction: It will sell as well as the "experts" are paid. Outside of them, not so much. Any serious HF professional can not take that joke of a trial 20mg vasotec Vs Max dose Diovan + a novel agent seriously. On top of that poor design & conflict of interest with 36% of the researchers on NVS payroll, some that didn't disclose, you have the down side of the NI & link to BA protein that can accelerate Alzheimers.
    Packer is like Gruber, fleecing millions & can provide any outcome the $$$ dictate.
     
  8. Anonymous

    Anonymous Guest

    No interest in doing any "expert" programs
     
  9. Anonymous

    Anonymous Guest

    Then (most likely)
    1, it well never sell &
    2, you'll be out of a job since you didn't utilize the enormous budget provided
     
  10. Anonymous

    Anonymous Guest

    LCZ is just another Serelaxin stinker! It represents another page of Novartis motivated greed to manipulate clinical trial design to make results look better than they really reflect. Novartis used non-standard (lower) doses of enalapril, yet allow maximal dose titration of LCZ696. Additionally, ~20% of potential patients washed out due to tolerability issues. This drug will likely help a niche group of patients, but its no billion dollar blockbuster, especially when patients will likely still have to step thru generic ACEs/ARBs before getting to paid branded LCZ.
     
  11. Anonymous

    Anonymous Guest

    Dog like Tekturna
     
  12. Anonymous

    Anonymous Guest

    The job postings have now been removed from the website. That can't be good.
     
  13. Anonymous

    Anonymous Guest

    They've been removed since they just shut down the CF team. Gotta give them any openings first. This company is ridiculous.
     
  14. Anonymous

    Anonymous Guest

    I am interviewing for the new hospital expansion, they are talking this is a block buster drug, from the sounds of it, not??? Its just 2 drugs already used but put together? Right?
     
  15. Anonymous

    Anonymous Guest

    We also called tekturna, valturna, starlix future blockbusters.
     
  16. Anonymous

    Anonymous Guest

    We also call Novartis Management, leadership. What a joke!
     
  17. Anonymous

    Anonymous Guest

    Oh boy. Here we go again.
     
  18. Anonymous

    Anonymous Guest

    This is a much needed medication in HF. Despite any limitations of the trial, the fact is this drug will be a blockbuster. As much as you are whining, you should be grateful to have a job (there are many CV and Hosp reps at other organizations who would kill to sell this drug). Also, think about the Amgen CV team with the absolutely ridiculous HF product they will be challenged with selling. I know this industry has created some entitled mind sets, but really...you are really complaining about selling this. Please resign before launch...please!
     
  19. Anonymous

    Anonymous Guest

    All you fucko's at corporate are the entitled ones. You take care of each other, come out of the woodwork to land a spot in cv all of a sudden beacuse we don't have much of anything else. Go spew you rhetoric somewhere else. Fact is the trial sucked, this will be another valturna and oh yes f u again.
     
  20. Anonymous

    Anonymous Guest

    All the noise around this drug is being created by Novartis it's called public relations. Try keeping it in perspective and save the killing to sell this drug as an internal thought sounds a little crazy